Market Place
Sourcing Support
ICU Medical & Otsuka Announce Joint Venture to Boost IV in America
12 Nov 2024 //
PR NEWSWIRE
IRLAB Receives Milestone of 2.5M For IRL757 Ph I Study in Older Adult
08 Oct 2024 //
ACCESSWIRE
Otsuka falls foul of most serious drug marketing breach, again
01 Oct 2024 //
FIERCE PHARMA
FDA Issues Form 483 to Otsuka Pharmaceutical Co.
30 Aug 2024 //
FDA
BITT Announces Otsuka Research Deal And New NIH Funding For TNFR2 Trial
16 Aug 2024 //
BUSINESSWIRE
Otsuka And Lundbeck Present REXULTI® Data At AAIC 2024
31 Jul 2024 //
BUSINESSWIRE
Ionis Expands Licensing Agreement With Otsuka For Donidalorsen In Angioedema
18 Jun 2024 //
PR NEWSWIRE
Otsuka backs Bradley Cooper-produced doc film about caregivers
09 May 2024 //
FIERCE PHARMA
Rexulti the surprise winner in April`s TV drug ad spending list
07 May 2024 //
FIERCE PHARMA
Notice on Treasury Shares Disposal as Restricted Stock
26 Apr 2024 //
PRESS RELEASE
Otsuka, Lundbeck sNDA for Brexpiprazole+Sertraline in PTSD
09 Apr 2024 //
PRESS RELEASE
Otsuka and Lundbeck’s schizophrenia treatment gains EC approval
28 Mar 2024 //
PHARMACEUTICAL TECHNOLOGY
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI
18 Mar 2024 //
BUSINESSWIRE
Otsuka and Sumitomo Revise License Agreement
15 Mar 2024 //
PRESS RELEASE
Otsuka Submits New Drug Application in Japan for Voclosporin
10 Nov 2023 //
PRESS RELEASE
Selected as METI`s "Model Project for the Promotion of PHR Services" Launch of a Healthcare Service
08 Nov 2023 //
PRESS RELEASE
MIREVO® Obtains Regulatory Approval, a First in Japan
08 Nov 2023 //
PRESS RELEASE
Otsuka Pharmaceutical Granted Silver Certification in PRIDE Index 2023
07 Nov 2023 //
PRESS RELEASE
New England Journal of Medicine Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab
06 Nov 2023 //
PRESS RELEASE
Otsuka Announces Personnel Changes
06 Nov 2023 //
PRESS RELEASE
Lundbeck, Otsuka dial down the drama for Rexulti agitation ad
13 Oct 2023 //
FIERCE PHARMA
Otsuka pens AAV deal with Shape Therapeutics for eye gene therapies
08 Sep 2023 //
ENDPTS
NephroDI Therapeutics and MSRD partner to develop therapy for NDI
23 Jun 2023 //
PHARMACEUTICAL TECHNOLOGY
FDA signs off on Otsuka and Lundbeck`s longer-acting Abilify
29 Apr 2023 //
FIERCE PHARMA
FDA backs Rexulti for first approval for agitation associated with Alzheimer’s dementia
12 Apr 2023 //
ENDPTS
Otsuka, Lundbeck eye Alzheimer`s indication in FDA adcomm
29 Mar 2023 //
ENDPTS
Schrödinger expands neuroscience work with BMS, Otsuka deals
09 Jan 2023 //
FIERCE BIOTECH
Otsuka and Lundbeck Announce FDA Acceptance of sNDA for Brexpiprazole
07 Jan 2023 //
BUSINESSWIRE
Otsuka Group Selected for CDP Climate Change A List
13 Dec 2022 //
PRESS RELEASE
Announcement of Price Revisions for Specified Products
06 Dec 2022 //
PRESS RELEASE
Otsuka Pharma Tokushima Itano Factory Receives 2022 Award for Excellent Greening
05 Dec 2022 //
PRESS RELEASE
Otsuka receives vital Lupkynis MHRA authorisation
30 Nov 2022 //
PHARMATIMES
In new deal, AstraZeneca places small bet on `critical but challenging` target
28 Nov 2022 //
ENDPTS
New skin care brand Introducing Sakuraé Double Action Serum- Japan`s first "double brightening" effect
24 Nov 2022 //
PRESS RELEASE
Otsuka Pharmaceutical Finalizes Business Collaboration Agreement for Horizontal Recycling of PET Bottles
21 Nov 2022 //
PRESS RELEASE
Announcement of price revisions for the Oral Rehydration Solution OS-1 series
21 Nov 2022 //
PRESS RELEASE
Otsuka Announces the Launch in Japan of Auto-Injector Dosage Form for AJOVY
18 Nov 2022 //
PRESS RELEASE
Announcement of Termination of Agreements with Takara Bio for NY-ESO-1
10 Nov 2022 //
PRESS RELEASE
Otsuka Opens Osaka Research Center for Drug Discovery in Osaka Prefecture, Japan
07 Nov 2022 //
PRESS RELEASE
Announced Consistent Reduction of Blood Pressure in Pooled Analysis of Three Clinical Trials at AHA 2022
07 Nov 2022 //
PRESS RELEASE
FDA greenlights Otsuka subsidiary`s bile duct cancer drug
04 Oct 2022 //
ENDPTS
Otsuka And Lundbeck Generate Exploratory Data In Major Depressive Disorder
03 Oct 2022 //
NEWSWISE
Otsuka Medical Devices Announces Results of RADIANCE II
19 Sep 2022 //
BUSINESSWIRE
FDA accepts Otsuka filing for long-acting schizophrenia drug
14 Sep 2022 //
FIERCEPHARMA
Otsuka and H. Lundbeck Sue Viatris Over Abilify Maintena Again
06 Sep 2022 //
FDANEWS
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens
17 Aug 2022 //
PRNEWSWIRE
5 pharmas lambasted by UK watchdog for marketing snafus
01 Aug 2022 //
FIERCEPHARMA
Otsuka receives positive CHMP opinion for LupkynisTM (voclosporin) for the treatment of active lupus nephritis
22 Jul 2022 //
PRESS RELEASE
Akebia Regaining Rights to Vadadustat in US, Europe, China and more
30 Jun 2022 //
PRNEWSWIRE
Lundbeck, Otsuka drug cut agitation in Alzheimer`s patients
28 Jun 2022 //
FIERCEPHARMA
EMA Commences Review of Aripiprazole 2-Month Long-Acting Injectable
17 Jun 2022 //
PRESS RELEASE
Akebia Terminates License Agreements with Otsuka
17 May 2022 //
BIOSPACE
Akebia Drops Bid to Bar AstraZeneca From Anemia Drug Patent Suit
07 Apr 2022 //
BLOOMBERG
Otsuka, Lundbeck Announce FDA Approval of sNDA for REXULTI
06 Jan 2022 //
BUSINESSWIRE
Biogen-Eisai, Samsung-Roche, Sunovion-Otsuka—Fierce Pharma Asia
01 Oct 2021 //
FIERCEPHARMA
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-TB Combo
09 Aug 2021 //
BUSINESSWIRE
FDA rejects professor’s petition seeking to pull Otsuka kidney disease drug
20 Jul 2021 //
ENDPTS
Otsuka signs three-year collaboration with Holmusk to improve digital health
08 Jul 2021 //
PR NEWSWIRE
